ID   YAPC
AC   CVCL_1794
DR   CLO; CLO_0009711
DR   EFO; EFO_0006778
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472904
DR   BioSample; SAMN03473329
DR   BioSample; SAMN10988032
DR   Cell_Model_Passport; SIDM00411
DR   ChEMBL-Cells; CHEMBL3307253
DR   ChEMBL-Targets; CHEMBL612815
DR   Cosmic; 909904
DR   Cosmic; 2046537
DR   Cosmic; 2434108
DR   Cosmic-CLP; 909904
DR   DepMap; ACH-000332
DR   DSMZ; ACC-382
DR   EGA; EGAS00001000978
DR   GDSC; 909904
DR   GEO; GSM887742
DR   GEO; GSM888837
DR   GEO; GSM1670584
DR   IARC_TP53; 27267
DR   IGRhCellID; YAPC
DR   LiGeA; CCLE_222
DR   LINCS_LDP; LCL-1792
DR   PharmacoDB; YAPC_1679_2019
DR   Progenetix; CVCL_1794
DR   Wikidata; Q54995282
RX   PubMed=9533774;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=25167228;
RX   PubMed=25485619;
RX   PubMed=26216984;
RX   PubMed=27397505;
RX   PubMed=29444439;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=YAPC
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: NCI RAS program mutant KRAS cell line panel.
CC   Population: Japanese.
CC   Doubling time: ~48 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Metabolome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0.82%; East Asian, North=85.11%; East Asian, South=13.9%; South Asian=0.15%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Misspelling: YPAC; In obsoleted EFO EFO_0002393 and in ArrayExpress E-MTAB-38.
CC   Derived from sampling site: Ascites.
ST   Source(s): Cosmic-CLP; DSMZ; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 8,12
ST   D16S539: 9
ST   D18S51: 17
ST   D21S11: 31,31.2
ST   D3S1358: 17
ST   D5S818: 11,13
ST   D7S820: 9,11
ST   D8S1179: 13,15
ST   FGA: 21,22
ST   Penta D: 10,13
ST   Penta E: 5,19.4
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 16,17 (Cosmic-CLP; DSMZ)
ST   vWA: 17 (PubMed=25877200)
DI   NCIt; C3850; Pancreatic carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   43Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 16-12-21; Version: 32
//
RX   PubMed=9533774; DOI=10.1002/(SICI)1097-0215(19980330)76:1<141::AID-IJC22>3.0.CO;2-E;
RA   Yamada T., Okajima F., Adachi M., Ohwada S., Kondo Y.;
RT   "Growth dependency of a new human pancreatic cancer cell line, YAPC,
RT   on autocrine interleukin-1alpha stimulation.";
RL   Int. J. Cancer 76:141-147(1998).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25167228; DOI=10.1038/bjc.2014.475;
RA   Hamidi H., Lu M., Chau K., Anderson L., Fejzo M., Ginther C.,
RA   Linnartz R., Zubel A., Slamon D.J., Finn R.S.;
RT   "KRAS mutational subtype and copy number predict in vitro response of
RT   human pancreatic cancer cell lines to MEK inhibition.";
RL   Br. J. Cancer 111:1788-1801(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26216984; DOI=10.1073/pnas.1501605112;
RA   Daemen A., Peterson D., Sahu N., McCord R., Du X.-N., Liu B.,
RA   Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R.,
RA   Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.L.,
RA   Manning G., Settleman J., Hatzivassiliou G., Evangelista M.;
RT   "Metabolite profiling stratifies pancreatic ductal adenocarcinomas
RT   into subtypes with distinct sensitivities to metabolic inhibitors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//